Cardiologists, Cardiovascular Nurses, Endocrinologists, Family Practitioners, Internists, Lipidologists, Lipid Specialists, Nephrologists, Nurse Practitioners, Pharmacists, Dietitians, PhDs, Physicians Assistants, Primary Care Physicians
Guidelines/Recommendations
1. | Compare and contrast approaches to lipid management for ASCVD prevention advocated by the NLA's Recommendations for Patient-Centered Management of Dyslipidemia with the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol | 2. | Analyze the effectiveness of risk assessment approaches of the NLA's Recommendations for Patient-Centered Management of Dyslipidemia and the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol |
3. | Recognize differences in lipid management recommendations for special populations | 4. | Compare and contrast the role of lifestyle and pharmacologic therapies for ASCVD prevention advocated by the NLA's Recommendations for Patient-Centered Management of Dyslipidemia with the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol |
1. | Compare and contrast approaches to lipid management for ASCVD prevention advocated by the NLA's Recommendations for Patient-Centered Management of Dyslipidemia with the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol |
2. | Analyze the effectiveness of risk assessment approaches of the NLA's Recommendations for Patient-Centered Management of Dyslipidemia and the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol |
3. | Recognize differences in lipid management recommendations for special populations |
4. | Compare and contrast the role of lifestyle and pharmacologic therapies for ASCVD prevention advocated by the NLA's Recommendations for Patient-Centered Management of Dyslipidemia with the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol |
FACULTY DISCLOSURES | ||
NAME | RELATIONSHIP | COMPANY |
Peter Jones, MD | Consultant | Amgen, Atherotech, Inc., Merck & Co., Inc., Sanofi-aventis/Regeneron Pharmaceuticals, Inc. |
Speakers Bureau | Merck & Co., Inc. | |
Pamela Morris, MD | Advisory Board | Aegerion Pharmaceuticals, Inc., AstraZeneca, Genzyme Corporation |
Speakers Bureau | Aegerion Pharmaceuticals, Inc., AstraZeneca, Genzyme Corporation | |
Carl Orringer, MD | Consultant | Merck & Co., Inc. |
PLANNER DISCLOSURES | ||
Robert Wild, MD, PhD, MPH (CME Reviewer) | Consultant | Atherotech, Inc. |
AKH Staff/Planners | N/A | Nothing to Disclose |
NLA Staff/Planners | N/A | Nothing to Disclose |
Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |